GLP-1 receptor agonists and cardiovascular outcome trials: An update.
Aged
Blood Pressure
/ drug effects
Cardiovascular Diseases
/ epidemiology
Cardiovascular System
/ drug effects
Case-Control Studies
Diabetes Mellitus, Type 2
/ drug therapy
Endothelium, Vascular
/ drug effects
Glucagon-Like Peptide 1
/ administration & dosage
Glucagon-Like Peptide-1 Receptor
/ agonists
Glucagon-Like Peptides
/ administration & dosage
Humans
Hypoglycemic Agents
/ administration & dosage
Insulin Resistance
/ physiology
Liraglutide
/ administration & dosage
Middle Aged
Randomized Controlled Trials as Topic
Risk Factors
United States
/ epidemiology
United States Food and Drug Administration
Weight Loss
/ drug effects
Cardiovascular disease
Diabetes mellitus
Randomised controlled trials
Treatment
Journal
Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
ISSN: 2241-5955
Titre abrégé: Hellenic J Cardiol
Pays: Netherlands
ID NLM: 101257381
Informations de publication
Date de publication:
Historique:
received:
06
09
2018
revised:
09
11
2018
accepted:
14
11
2018
pubmed:
12
12
2018
medline:
2
6
2020
entrez:
12
12
2018
Statut:
ppublish
Résumé
Major cardiovascular (CV) outcome trials with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are currently available. These agonists have proven their CV safety, in harmony with the US Food and Drug Administration (FDA) recommendation for antidiabetic drugs. The potential cardioprotective effect of incretin-based therapies is attributed to their multiple non-glycaemic actions in the CV system, including changes in insulin resistance, weight loss, reduction in blood pressure, improved lipid profile and direct effects on the heart and vascular endothelium. Liraglutide, semaglutide and albiglutide have been demonstrated to reduce the risk of major adverse cardiac events (MACE), whereas lixisenatide and extended-release exenatide had a neutral effect. Thus, it is conceivable that there are different drug-specific properties across the class of GLP-1 RAs. In this review, we discuss the results of the five recently published randomised CV outcome trials with GLP-1 RAs, along with the potential differences and the pleiotropic actions of these agents on the CV system.
Identifiants
pubmed: 30528435
pii: S1109-9666(18)30408-1
doi: 10.1016/j.hjc.2018.11.008
pii:
doi:
Substances chimiques
Glucagon-Like Peptide-1 Receptor
0
Hypoglycemic Agents
0
semaglutide
53AXN4NNHX
rGLP-1 protein
5E7U48495E
Glucagon-Like Peptides
62340-29-8
Liraglutide
839I73S42A
Glucagon-Like Peptide 1
89750-14-1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
347-351Informations de copyright
Copyright © 2018 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved.